ADAnna Maria Dworakowska

Anna Maria Dworakowska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna Maria Dworakowska has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Renoprotective vs. Antihypertensive Dosing of Renin–Angiotensin System Inhibitors in Chronic Kidney Disease: Analysis of Summary of Product Characteristics of Medicinal Products Authorized in Poland

    by Marta Maciejczyk, Anna Maria Dworakowska, Magdalena Bujalska-Zadrożny

    Introduction: Renin–angiotensin system inhibitors are central to antihypertensive and nephroprotective treatment in chronic kidney disease. However, renal dosing information in Summaries of Product Characteristics (SmPCs) may differ between products and may not reflect current kidney function assessment. Objectives: We systematically evaluated dosing recommendations for single-component ACE inhibitors and angiotensin receptor blockers authorized in Poland, focusing on renal impairment and nephroprotective indications. Patients and methods: This cross-sectional content analysis included SmPCs for medicinal products classified under ATC codes C09AA and C09CA. Documents were retrieved from Polish and European regulatory sources. Data were extracted on indications, antihypertensive and nephroprotective dosing, renal dose-adjustment recommendations, renal function parameters, estimation formulas, thresholds, dose limits, and dialysis-related statements. Results: The final sample included 282 medicinal products. Hypertension was an approved indication in all products, whereas nephroprotective indications were identified in 106 (37.6%). Creatinine clearance was the predominant renal function parameter for dose adjustment, appearing in 190 products (67.4%). No SmPC used glomerular filtration rate for dose adjustment, although GFR was mentioned in 16 products, mainly in contraindications involving aliskiren. References to renal function estimation formulas were rare; Cockcroft–Gault was explicitly mentioned in a few products, while MDRD and CKD-EPI were absent. Nephroprotective and antihypertensive maximum doses were identical in most products, but differences were identified in 15 (14.2%), mainly lisinopril and benazepril. Conclusions: SmPCs for ACE inhibitors and angiotensin receptor blockers authorized in Poland show substantial heterogeneity in renal dosing recommendations. Greater harmonization and alignment with contemporary kidney function assessment would improve clinical applicability.

  • Open Access

    Structured Pharmacist-Led Vaccine Recommendation and Coadministration in Community Pharmacies: Real-World Evidence from Poland

    by Ewa Kuczwalska, Anna Maria Dworakowska, Magdalena Skarżyńska, Magdalena Bujalska-Zadrożny

    Background and Objectives: Community pharmacies in Poland administer an expanding range of adult vaccines, including influenza, COVID-19, respiratory syncytial virus (RSV), herpes zoster and pneumococcal vaccines. While pharmacist vaccination services are increasingly available, evidence on structured approaches supporting vaccine coadministration remains limited. This study assessed whether a structured pharmacist-led recommendation and coadministration protocol was associated with greater uptake of multiple vaccines and same-day coadministration in routine community pharmacy practice. Methods: This non-randomized real-world study used anonymized vaccination records from three community pharmacies in northern Poland between 1 August 2025 and 31 March 2026. One pharmacy implemented a multicomponent protocol combining proactive identification of eligible patients, presumptive recommendation and same-day coadministration, while two comparator pharmacies operated under routine practice. Outcomes included the mean number of vaccine types per patient, the proportion of patients receiving at least two of five analyzed vaccines, same-day coadministration among multi-vaccine patients, and the RSV-to-(influenza + COVID-19) vaccination ratio. A Poisson regression model with robust standard errors was used to assess relative RSV uptake. As the dataset comprised only patients who received at least one vaccination, these findings describe vaccination patterns among presenting, already-vaccinated patients rather than uptake relative to the total eligible or registered pharmacy population, for which denominators were not available. Results: Overall, 3248 patients contributed 5505 unique patient-vaccine events. The intervention pharmacy achieved a higher mean number of vaccine types per patient than comparator pharmacies (2.08 vs. approximately 1.54). The proportion of patients receiving at least two vaccine types was 73.6% (685/931) in the intervention pharmacy compared with 42.7% (990/2317) in comparator pharmacies. Among multi-vaccine patients, same-day coadministration occurred in 92.7% (635/685) of intervention-site patients versus 73.1% (724/990) in comparator pharmacies. Triple-vaccine coadministration visits were observed exclusively in the intervention pharmacy. RSV uptake was higher in the intervention pharmacy (incidence rate ratio 2.17; 95% CI 1.67–2.84; p < 0.001). An age- and sex-adjusted analysis of multi-vaccine uptake yielded a materially unchanged association (adjusted OR 4.42; 95% CI 3.71–5.28) relative to the unadjusted estimate (OR 3.73; 95% CI 3.16–4.41). The exploratory temporal-interaction analysis was not statistically significant when all months were included (interaction IRR 0.84; 95% CI 0.69–1.02; p = 0.085), whereas a sensitivity analysis excluding March 2026 suggested a narrowing relative RSV-rate advantage over time (interaction IRR 0.79; 95% CI 0.70–0.89; p < 0.001). Conclusions: A structured pharmacist-led recommendation and coadministration protocol was associated with substantially greater uptake of multiple vaccines among vaccinated patients, more frequent same-day coadministration and higher RSV uptake compared with routine practice. These findings suggest that workflow organization, proactive patient identification and systematic recommendation strategies may improve the efficiency of adult vaccination delivery in community pharmacies. Larger multicenter studies are warranted to confirm these findings and evaluate individual protocol components.

  • Open Access

    Effectiveness of pharmacist-delivered vaccination recommendations for herpes zoster: a systematic review

    by Ewa Kuczwalska, Anna Maria Dworakowska, Magdalena Skarżyńska, Magdalena Bujalska-Zadrożny

    Introduction: Herpes zoster (HZ) remains an important cause of morbidity among older adults despite the availability of effective vaccines. Recommendations from healthcare professionals are among the strongest determinants of adult vaccination uptake, and community pharmacists are increasingly involved in vaccination recommendations. Objectives: To systematically review and critically appraise the evidence on the effectiveness of pharmacist-delivered recommendation strategies in increasing confirmed HZ vaccination uptake and recombinant zoster vaccine (RZV) series completion. Patients and methods: PubMed, Embase, and the Cochrane Library were searched from database inception to October 14, 2025. Studies evaluating pharmacist-delivered recommendation interventions aimed at increasing HZ vaccination were included if they reported quantitative outcomes for confirmed vaccination uptake or RZV series completion. Data on study characteristics, interventions, and vaccination outcomes were extracted. Risk of bias was assessed using RoB 2 and ROBINS-I. Results: Nine studies met the eligibility criteria for the primary synthesis of confirmed vaccination outcomes. Eight evaluated ZVL (Zostavax), whereas only one specifically assessed RZV (Shingrix) series completion. Seven studies were conducted in the United States and used predominantly non-randomized designs. Settings ranged from single community pharmacies to networks of 159 pharmacies. Positive effects on confirmed HZ vaccination uptake or RZV series completion were reported in five studies. The strongest evidence came from a cluster randomized controlled trial involving 16 pharmacies, in which automated telephone recommendations increased vaccination rates from 0.72 to 2.60% (OR 3.69; 95% CI 2.64–5.15). Additional positive findings were observed for personalized outreach and pharmacist telephone follow-up aimed at improving RZV series completion. Three studies reported no improvement or decreased HZ vaccination rates. The overall certainty of evidence was limited by methodological weaknesses: six of eight non-randomized studies were rated as having serious risk of bias, and only one randomized trial was available. Conclusion: Pharmacist-delivered recommendation strategies may improve HZ vaccination uptake and RZV series completion, particularly when implemented through proactive patient outreach. However, the current evidence base remains limited by the predominance of non-randomized studies and substantial risk of bias. Well-designed randomized and quasi-experimental studies are needed to determine the independent effectiveness of pharmacist-delivered vaccination recommendations.


  • Open Access

    Renal Dose Adjustment in European Primary Care: Clinical Nuances and Practical Challenges

    by Anna Maria Dworakowska, Jolanta Małyszko, Magdalena Bujalska-Zadrożny

    Appropriate dose adjustment of renally eliminated medicines is central to safe pharmacotherapy in patients with chronic kidney disease; yet, in European primary care, it is systematically undermined not by lack of knowledge, but by structural misalignment between laboratory reporting, regulatory product information, and clinical guidelines. This Perspective argues that the core barrier to optimal renal dose adjustment is a mismatch between routinely reported indexed eGFR and dosing requirements based on absolute renal function, compounded by persistent regulatory reliance on the Cockcroft–Gault equation despite its known limitations. We show how these structural inconsistencies, together with patient-related factors such as frailty, ageing, and body size, generate uncertainty at the point of prescribing and contribute to persistent variability in dosing decisions. To address this challenge, we propose a structured, context-aware renal dosing framework designed for routine primary care. The framework integrates regulatory guidance, multiple methods of renal function estimation, and patient-specific modifiers into a stepwise decision process. Clinical vignettes illustrate how divergent renal function estimates and regulatory requirements can lead to different dosing decisions in everyday practice. By reframing renal dose adjustment as a context-driven clinical process rather than a purely equation-based task, this Perspective highlights the need for regulatory alignment and pragmatic decision tools to improve prescribing quality in patients with chronic kidney disease.


  • Open Access

    Assessment Study of ChatGPT-3.5’s Performance on the Final Polish Medical Examination: Accuracy in Answering 980 Questions

    by Julia Siebielec, Michal Ordak, Agata Oskroba, Anna Dworakowska, Magdalena Bujalska-Zadrozny

    Background/Objectives: The use of artificial intelligence (AI) in education is dynamically growing, and models such as ChatGPT show potential in enhancing medical education. In Poland, to obtain a medical diploma, candidates must pass the Medical Final Examination, which consists of 200 questions with one correct answer per question, is administered in Polish, and assesses students’ comprehensive medical knowledge and readiness for clinical practice. The aim of this study was to determine how ChatGPT-3.5 handles questions included in this exam. Methods: This study considered 980 questions from five examination sessions of the Medical Final Examination conducted by the Medical Examination Center in the years 2022–2024. The analysis included the field of medicine, the difficulty index of the questions, and their type, namely theoretical versus case-study questions. Results: The average correct answer rate achieved by ChatGPT for the five examination sessions hovered around 60% and was lower (p < 0.001) than the average score achieved by the examinees. The lowest percentage of correct answers was in hematology (42.1%), while the highest was in endocrinology (78.6%). The difficulty index of the questions showed a statistically significant correlation with the correctness of the answers (p = 0.04). Questions for which ChatGPT-3.5 provided incorrect answers had a lower (p < 0.001) percentage of correct responses. The type of questions analyzed did not significantly affect the correctness of the answers (p = 0.46). Conclusions: This study indicates that ChatGPT-3.5 can be an effective tool for assisting in passing the final medical exam, but the results should be interpreted cautiously. It is recommended to further verify the correctness of the answers using various AI tools.


  • Open Access

    Opinions of pharmacists in Poland on changes in professional competencies due to the COVID-19 pandemic

    by Joanna Oberska, Anna Dworakowska, Małgorzata Kozłowska-Wojciechowska

  • Adherence to guidelines for pharmacological treatment of young adults with myocardial infarction in Poland: Data from Polish Registry of Acute Coronary Syndromes (PL‐ACS)

    by Agnieszka Lisowska, Magdalena Makarewicz‐Wujec, Anna M. Dworakowska, Małgorzata Kozłowska‐Wojciechowska

    What is known and objective Myocardial infarction (MI) in young adults accounts for up to 10% of all cases. Regarding life expectancy and professional activity, it is extremely important to restore and maintain young patients’ full performance. Therefore, secondary prevention is especially vital in this group of patients. The paper focuses on the analysis of pharmacotherapy in young MI patients in Poland, assessing disparities between the European Society of Cardiology guidelines and clinical practice, and regional differences among the provinces. Methods The analysis was conducted using the data from a nationwide, observational, multicentre, prospective study—the Polish Registry of Acute Coronary Syndromes (PL‐ACS). The data were collected from patients ≤45 years old with MI who were hospitalized in the period 2010‐2014. Results and discussion A retrospective study included 6367 MI patients. They constituted 3.9% of all the patients with MI in Poland. Despite the fact that during hospitalization regional differences were observed in case of acetylsalicylic acid (range 70.3%‐93.8%), β‐blockers (range 50.0%‐79.6%), statins (range 53.4%‐85.7%) and angiotensin‐converting enzyme inhibitors (range 46.9%‐75.0%), the majority of patients received the drugs according to the guidelines. Regional differences found at discharge also regarded those medications, but the range of observed variations was smaller. On average, three‐quarter of patients received guideline‐recommended medications. Still, in some provinces, almost a quarter of patients were administered those medications only at discharge. What is new and conclusion In the study population, there were significant differences between the provinces regarding pharmacotherapy during hospitalization, which concerned major groups of medications. However, pharmacotherapy indicated at discharge revealed fewer regional differences and adhered to guideline recommendations to a greater extent. Nevertheless, there is still some room for improvement, especially with regard to pharmacotherapy during hospitalization.


  • Older adults’ strategies to prevent episodic medication non-adherence: results from a qualitative study

    by Anna Maria Dworakowska, Adrianna Aniszewska, Małgorzata Kozłowska-Wojciechowska

    Purpose The purpose of the study was to explore methods and routines used by older adults to remember to take medications.


  • Replacement of saturated andtrans-fatty acids in the dietv.CVD risk in the light of the most recent studies

    by Magdalena Makarewicz-Wujec, Anna Dworakowska, Małgorzata Kozłowska-Wojciechowska

    To present and discuss results of the most recent studies pertaining to the effects of consumption of different types of fatty acids on the risk of CVD. The aim was also an attempt to answer the question of whether a revision of the current recommendations is necessary. A review of prospective cohort studies, systematic reviews and meta-analyses published in 2014–2017 on the effects of SFA and trans-fatty acid (TFA) intakes as well as various models of their replacement in the diet on CVD risk. Results of the new large prospective cohort studies pertaining to the effect of SFA consumption on CVD risk are contradictory. Similarly, the recent meta-analyses of clinical trials related to the effects of SFA substitution on CVD risk provided extremely different results, which is related to the application of different inclusion and exclusion criteria. Differences in results of randomised controlled trials may be caused by different methodologies of dietary parameter changes, varying duration of studies, as well as the time at which they were carried out. It is extremely difficult to extrapolate results of recent studies to contemporary recommendations. It seems that there is a need for properly randomised studies on large groups, with good control of dietary and non-dietary parameters, which account for not only the sum of SFA and TFA, but also their source. Only such studies will allow for full evaluation of an effect of substituting SFA and TFA on cardiovascular risk.